Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309–22.

Article  CAS  PubMed  Google Scholar 

Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7:e456–e468.

Article  PubMed  Google Scholar 

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017;376:1311–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022;387:132–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:874–85.

Article  CAS  PubMed  Google Scholar 

Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016;3:e340–e351.

Article  PubMed  Google Scholar 

Cook G, Royle K, O’Connor S, Cairns DA, Ashcroft AJ, Williams CD, et al. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT / UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phasetrial. Br J Haematol. 2019;185:450–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldschmidt H, Baertsch M-A, Schlenzka J, Becker N, Habermehl C, Hielscher T, et al. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. 2021;35:1134–44.

Article  CAS  PubMed  Google Scholar 

Gagelmann N, Eikema D-J, Koster L, Caillot D, Pioltelli P, Lleonart JB, et al. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2019;25:2134–42.

Article  CAS  Google Scholar 

Drozd-Sokołowska J, Gras L, Zinger N, Snowden JA, Arat M, Basak G, et al. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT. Bone Marrow Transpl. 2022;57:633–40.

Article  Google Scholar 

Davis JA, Sborov DW, Wesson W, Julian K, Abdallah A-O, McGuirk JP, et al. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transpl Cell Ther. 2023;29:567–71.

Article  CAS  Google Scholar 

Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, et al. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transpl. 2024;59:647–52.

Article  CAS  Google Scholar 

Mohty M, Hübel K, Kröger N, Aljurf M, Apperley J, Basak GW, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2014;49:865–72.

Article  CAS  Google Scholar 

Czerw T, Sadus-Wojciechowska M, Michalak K, Najda J, Mendrek W, Sobczyk-Kruszelnicka M, et al. Increased Efficacy of Stem Cell Chemomobilization with Intermediate-Dose Cytarabine Plus Granulocyte Colony-Stimulating Factor (G-CSF) Compared with G-CSF Alone in Patients with Multiple Myeloma: Results of a Randomized Trial. Biol Blood Marrow Transpl. 2019;25:248–55.

Article  CAS  Google Scholar 

Dhakal B, Zhang M-J, Burns LJ, Tang X, Meyer C, Mau L-W, et al. Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. Haematologica. 2023;108:2249–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2014;20:295–308.

Article  Google Scholar 

Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, et al. Poor Mobilization of Hematopoietic Stem Cells—Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation. Biol Blood Marrow Transpl. 2010;16:490–9.

Article  CAS  Google Scholar 

Ozsan GH, Micallef IN, Dispenzieri A, Kumar S, Lacy MQ, Dingli D, et al. Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma. Am J Hematol. 2012;87:1–4.

Article  CAS  PubMed  Google Scholar 

Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, Coluccia P, et al. Management of poor peripheral blood stem cell mobilization: Incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci. 2009;41:33–37.

Article  PubMed  Google Scholar 

DiPersio JF, Stadtmauer EA, Nademanee A, Micallef INM, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–6.

Article  CAS  PubMed  Google Scholar 

Milone G, Martino M, Spadaro A, Leotta S, Di Marco A, Scalzulli P, et al. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol. 2014;164:113–23.

Article  CAS  PubMed  Google Scholar 

Farina L, Guidetti A, Spina F, Roncari L, Longoni P, Ravagnani F, et al. Plerixafor ‘on demand’: results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF. Bone Marrow Transpl. 2014;49:453–5.

Article  CAS  Google Scholar 

Hübel K, Fresen MM, Apperley JF, Basak GW, Douglas KW, Gabriel IH, et al. European data on stem cell mobilization with plerixafor in non-Hodgkin’s lymphoma, Hodgkin’s lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transpl. 2012;47:1046–50.

Article  Google Scholar 

Olivieri A, Marchetti M, Lemoli R, Tarella C, Iacone A, Lanza F, et al. Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transpl. 2012;47:342–51.

Article  CAS  Google Scholar 

Basak GW, Mikala G, Koristek Z, Jaksic O, Basic-Kinda S, Cegledi A, et al. Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it’s not too late. Leuk Lymphoma. 2011;52:1711–9.

Article  CAS  PubMed  Google Scholar 

Nahi H, Celanovic M, Liu Q, Lund J, Peceliunas V. A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor. Biol Blood Marrow Transpl. 2019;25:34–40.

Article  CAS  Google Scholar 

Micallef IN, Stiff PJ, Nademanee AP, Maziarz RT, Horwitz ME, Stadtmauer EA, et al. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biol Blood Marrow Transpl. 2018;24:1187–95.

Article  CAS  Google Scholar 

Morris C, Chabannon C, Masszi T, Russell N, Nahi H, Kobbe G, et al. Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. Bone Marrow Transpl. 2020;55:356–66.

Article  CAS  Google Scholar 

Durie BGM, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.

Article  CAS  PubMed  Google Scholar 

R Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing. 2022. Available from: https://www.r-project.org/.

Olivieri A, Saraceni F, De Luca A. Focus on: Prognostic scores to predict stem cell mobilization. Transfus Apher Sci. 2024;63:103935.

Article  PubMed